Gene Editing Updates | CRISPR, Intellia, and Beam

We revisit gene editing stocks once per year because things move very slowly in this space. While there may be upwards of 27 gene editing stocks out there, our focus is on the three biggest – Beam Therapeutics BEAM, Intellia Therapeutics NTLA, and CRISPR Therapeutics CRSP. Each of these companies is racing to bring treatments to market using their respective gene editing technologies. Of these three gene editing companies, CRISPR seems to be the furthest ahead as they await regulatory approval - in the USA and UK/Europe - for the first gene editing enabled therapy, exa-cel. These updates on gene editing stocks provide investors with the latest news on the biggest players.

RESEARCH PIECES USED IN THIS VIDEO:
1. Revisiting the Three Biggest Gene Editing Stocks
2. Beam Therapeutics Stock: A Leader in Gene Editing Tech?
3. A Complete List of 27 Gene Editing Stocks

CHAPTERS:
Intro
AI Drug Discovery and Gene Editing Themes
An Approach to Gene Editing Investing
Beam Therapeutics Update
Intellia Therapeutics Update
CRISPR Therapeutics Update
Conclusion

ABOUT US:
This video is brought to you by Nanalyze, a media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #stocks in a language that is future-proof and easy to understand.

DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our YouTube videos or on our website, whether for the purpose of making an investment or otherwise.

#GeneEditing
$BEAM
$CRSP
$NTLA

[joepiv]

If you subscribe to our channel using the below link, our on-staff Romanian fortune teller will include your portfolio in her prayers this evening. 🔮

[markduda]

This is my favorite YouTube channel by a mile!

[xercesss]

100% with the conclusion.

For me it’s too risky and too expensive, even if the potential is here.

I think we have time regarding Crispr tech, no FOMO (it created a lots of bag holders).

Moreover there’s more interesting and cheaper companies at the moment.

[justinjohnson]

my favorite videos are the dividend ones. I've always like buying big companies that I know arent going to have problems.

[Volcorom]

Hey, thanks so much for your straight-to-the point videos. One of the few who cover gene editing stocks, and not only when they are in a hype cycle. My question: Do you consider Prime Medicine? Same pedigree as Beam.

[jonathanedwardgibson]

Generating combos is the easy part. Testing IRL, not models, is only viable way forward. Too many have lost too much in the last few to allow current drug approval ‘process’ unchecked.

[MusicAndParkour]

What gets me passionate about these stocks is I can see how much funding and investors are crucial for technology and science to advance cause one thing is to invent some method and other thing is to make it at a massive scale to it is efficient. From what I searched, CRISPR is financially backed by Vertex while Intellia is backed by Regeneron. This could be a disadvantage to Beam as there doesn´t seem to be backed in funding by any large company. Therefore if they start running out of cash, Intellia and CRISPR are more likely to get support these large companies who already invested a lot in them and they surely have more to invest, contrary to BEAM. On the other hand, if that doesn´t happen BEAM will be at an advantage because CRISPR and Intellia have to share some of their revenues with these two big partners. Any thoughts?

[KjiehTV]

If you could I’d love to see a video on bioprinting stocks I think the tech is very fascinating but most likely 20 years away from anything exciting.

[Dgkeys]

Any thoughts on whether the latest decision to federally control drug prices is having, or will have any significant impact on gene-editing stocks like these? It appears they're going after both the super popular, chronically used drugs for things like diabetes and blood pressure. But I think they are also going after the rare, one dose life-saving cures that cost 6 or 7 figures...

[geeone]

Hey, love your videos. What’s your opinion on Docgo, seems to be disruptive in its category.

[Frank]

Hi, what after beta thalessimia and sickle cell any approximation of Crisper's next FDA dates? (I'm in CRSPR thus the question. ) TY
Any FDAs dates for Beam?

[Frank]

Hi, do you think there will be a surrounding Crisper's FDA date in March of 2024? When is the next Crisper development date? Thank you. Should a small investor be active surrounding those dates?

[MrNegreanu]

Thanks for the great videos, high quality content.

Do you guys have any plans to look at the players in the upcoming obesity or Alzheimer’s pharma markets?

[MartintheMartian]

I hope It may approve soon keep praying

[Yomamaissoo]

It will be too late by the time you decide to invest